查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997277

早产和胎膜早破检测市场：按产品类型、技术、生物标记、最终用户和应用划分－2026-2032年全球市场预测

Preterm Birth & PROM Testing Market by Product Type, Technology, Biomarker, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，早产和胎膜早破 (PROM) 检测市场价值将达到 14.6 亿美元，到 2026 年将成长到 15.4 亿美元，到 2032 年将达到 21.4 亿美元，年复合成长率为 5.62%。

主要市场统计数据
基准年 2025 14.6亿美元
预计年份：2026年 15.4亿美元
预测年份 2032 21.4亿美元
复合年增长率 (%) 5.62%

动态实施临床优先事项、诊断工作流程和营运挑战，进而影响医疗保健机构中早产和胎膜早破检测。

早产和胎膜早破 (PROM) 的检测处于产科、新生儿护理和诊断技术创新的交叉领域。临床医生越来越依赖客观的生物标记和改进的检测流程来做出影响母婴结局的时效性决策。同时，实验室主任和采购团队面临越来越大的压力，需要在将新平台整合到现有诊断系统的同时，平衡准确性、检测能力和成本。

近期技术进步、实证方法和供应链变化如何重塑检测早产风险和胎膜早破的诊断策略。

近年来，早产风险和胎膜早破（PROM）风险的识别、监测和管理发生了变革性变化。分子诊断、免疫检测和照护现场技术的进步，使得检测结果的快速出具在不影响分析性能的前提下得以实现。同时，透过数位健康平台和检查室资讯系统（LIS）实现的更完善的数据整合，使临床医生能够将生物标记结果与电子健康记录趋势和决策支援演算法相结合。这些进步共同提高了临床医生对快速且可操作的诊断结果的期望。

了解 2025 年关税政策变更和进口成本压力将如何影响诊断测试供应链的韧性、筹资策略和部署计画。

2025 年前的关税环境为诊断设备製造商、经销商和医疗采购机构带来了更大的复杂性。进口关税的增加和关税分类的变化可能会推高设备、试剂盒和试剂的采购成本，迫使各机构重新评估筹资策略并实现供应商多元化。为此，一些製造商正在加快生产本地化进程，并对替代供应商进行认证，以降低风险并维持稳定的利润率。

基于细分的洞察，了解产品架构、最终用户需求和应用程式优先顺序如何决定部署模式和筹资策略。

详细的細項分析揭示了不同产品类型、最终用户和应用场景下技术采纳和使用模式的显着差异。在产品类型方面，诸如自动化ELISA分析仪、免疫检测分析仪和PCR系统等仪器和设备通常优先应用于高通量诊断检查室和大规模医院系统，因为这些场所对处理能力、准确性和与自动化检测系统的整合度要求极高。相较之下，试剂盒和检测方法（例如ELISA试剂盒、PCR检测套组和快速检测套组）的应用范围更为广泛。 ELISA和PCR试剂盒通常用于支援集中式检查室工作流程，而快速检测套组则可用于门诊和医院分诊等场景，帮助患者做出决策。

美洲、欧洲、中东和非洲以及亚太地区的区域诊断环境和医疗保健系统特征影响部署、报销和部署策略。

区域趋势对早产和胎膜早破检测的引入路径、报销机制以及与临床流程的整合有显着影响。在美洲，临床决策受到公立和私立保险公司、区域核心医疗机构以及医院和检查室之间高度整合的限制。这种环境有利于扩充性的设备平台和检验的试剂盒在整合的医疗保健系统中推广应用，同时也支持学术机构进行以本地为中心的创新。

竞争、伙伴关係策略和基于证据的差异化将决定哪些公司在早产和胎膜早破诊断领域的创新中处于主导。

早产和胎膜早破检测领域的竞争动态由成熟的诊断公司、专业试剂供应商以及将照护现场(PoC) 技术推向市场的敏捷创新者共同塑造。现有仪器製造商继续在平台可靠性、与检查室自动化系统的兼容性以及全球服务网路方面竞争，而新参与企业则透过独特的检测化学、简化的使用者介面和快速部署模式来脱颖而出。仪器製造商和检测开发商之间的策略合作和共同开发契约日益增多，这有助于加快市场共用速度并共享监管合规流程。

针对诊断设备製造商和医疗保健领导者的可操作策略重点，重点在于检验、弹性供应链、灵活的商业模式和支付方合作关係。

产业领导者应优先考虑多管齐下的策略，将产品创新与临床检验、供应链稳健性和支付方合作结合。首先，投资可操作的临床研究至关重要，这些研究应能证明诊断结果如何改变行政决策并改善母婴结局，从而获得临床医生的支持并推动医保报销方面的讨论。这些研究的设计应充分考虑真实世界的临床工作流程，并纳入多中心合作，以提高研究结果的普遍性。

采用严谨的调查方法，结合专家的直接访谈、技术文件和临床文献的整合，以检验诊断效能和实施注意事项。

本分析整合了同行评审的临床文献、监管指导文件、业界公开的技术规格以及对临床医生、实验室管理人员和采购负责人的访谈。该方法优先采用「三角验证」策略，将分析性能的证据与源自真实临床实践的临床效用和操作实施方面的见解相结合。在监管指导文件相关的情况下，其解读着重于其如何满足检验要求和上市后监测，而非特定司法管辖区的合规性检查清单。

概述诊断技术创新、对证据的期望以及将决定早产和胎膜早破检测未来方向的营运重点。

总而言之，在技术进步、对更高证据水平的期望以及营运需求的推动下，早产和胎膜早破检测的诊断格局正在迅速发展。临床医生和检查室管理人员越来越倾向于寻求不仅分析可靠，而且具有显着临床意义并能无缝融入临床流程的诊断方法。与供应链连续性和定价相关的成本压力正在促使采购和合约设计进行策略性调整，从而影响部署和检验计划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：早产及胎膜早破检测市场：依产品类型划分

  • 设备/器材
    • 自动ELISA分析仪
    • 免疫检测装置
    • PCR系统
  • 试剂盒和检测试剂盒
    • ELISA试剂盒
    • PCR检测套组
    • 快速检测套组
  • 试剂和耗材
    • 抗体
    • 缓衝液和培养基
    • 酵素和探针

第九章：早产及胎膜早破检测市场：依技术划分

  • 生化试验
  • 分子诊断
  • 生物物理和成像诊断方法

第十章：生物标记在早产和胎膜早破检测的市场

  • 蛋白质生物标记
  • 遗传和基因组标记
  • 微生物和感染疾病标记物

第十一章：早产和胎膜早破检测市场：依最终用户划分

  • 门诊治疗
  • 诊断检查室
  • 医院和诊所
  • 研究机构

第十二章：早产及胎膜早破检测市场：依应用领域划分

  • 诊断
  • 监测
  • 出于研究目的
  • 筛检

第十三章：早产及胎膜早破检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：早产及胎膜早破检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 早产与胎膜早破市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国早产和胎膜早破检测市场

第十七章：中国早产和胎膜早破检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • bioMerieux SA
  • Danaher Corporation
  • Eurofins Scientific SE
  • Hologic, Inc.
  • Qiagen NV
  • Quidel Corporation
  • Revvity, Inc.
  • Rhomed SpA
  • Roche Diagnostics GmbH
  • Sekisui Medical Co., Ltd.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market was valued at USD 1.46 billion in 2025 and is projected to grow to USD 1.54 billion in 2026, with a CAGR of 5.62%, reaching USD 2.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.46 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 2.14 billion
CAGR (%) 5.62%

A dynamic introduction to clinical priorities, diagnostic workflows, and operational pressures shaping preterm birth and PROM testing across healthcare settings

Preterm birth and premature rupture of membranes (PROM) testing sit at the intersection of obstetrics, neonatal care, and diagnostic innovation. Clinicians increasingly rely on objective biomarkers and improved testing workflows to make time-sensitive decisions that affect maternal and neonatal outcomes. Meanwhile, laboratory directors and procurement teams face mounting pressure to balance accuracy, throughput, and cost while integrating new platforms into existing diagnostic ecosystems.

In clinical practice, early and precise identification of PROM and imminent preterm delivery can materially influence treatment pathways, including administration of corticosteroids, antibiotics, tocolytics, and decisions regarding transfer to higher-acuity centers. As a result, innovations that deliver rapid, reliable results in near-patient and laboratory settings are drawing significant attention from clinical leaders. Concurrently, regulatory scrutiny and evidence-based guideline updates are reshaping the expectations for test validation, clinical utility demonstrations, and post-market surveillance.

From an operational perspective, the diagnostic landscape is evolving toward modular workflows that support high-volume laboratory automation as well as decentralized testing at ambulatory and hospital sites. Cross-disciplinary collaboration among obstetricians, perinatologists, laboratorians, and hospital administrators is becoming central to implementing testing protocols that are clinically meaningful and operationally sustainable. Taken together, these dynamics underscore the critical role of diagnostic testing innovation in improving prenatal care pathways and reducing downstream neonatal complications.

How recent technological, evidence, and supply chain shifts are reshaping diagnostic strategies for detecting preterm birth risks and premature rupture of membranes

Recent years have seen a transformative shift in how preterm birth risk and PROM are identified, monitored, and managed. Advances in molecular diagnostics, immunoassays, and point-of-care technologies have enabled faster turnaround times without sacrificing analytical performance. Concurrently, digital health platforms and laboratory information systems are improving data integration, enabling clinicians to combine biomarker results with electronic health record trends and decision support algorithms. These developments have collectively raised clinician expectations for rapid, actionable diagnostic outputs.

Moreover, the diagnostic community has moved toward greater emphasis on clinical utility and pragmatic validation studies. Rather than relying solely on laboratory performance metrics, developers and adopters increasingly demand real-world evidence that links test results to measurable changes in patient management and outcomes. This shift has prompted closer engagement between test manufacturers and clinical investigators to design studies that demonstrate meaningful clinical endpoints.

At the same time, supply chain resilience and reagent sustainability have emerged as strategic priorities. Test developers are investing in reagent stabilization, alternative sourcing strategies, and consumable standardization to reduce operational disruptions. Consequently, adoption decisions now factor not just analytical accuracy but also long-term supply continuity and integration ease. Together, these shifts are reshaping product roadmaps and procurement strategies across clinical and laboratory stakeholders.

Understanding how evolving tariff policies and import cost pressures in 2025 are impacting supply chain resilience, procurement tactics, and deployment timelines for diagnostic testing

The tariff environment entering into 2025 introduced a layer of complexity for diagnostic manufacturers, distributors, and healthcare purchasing organizations. Increased import duties and changes to customs classifications have the potential to elevate landed costs for instruments, kits, and reagents, prompting organizations to reassess sourcing strategies and supplier diversification. In response, some manufacturers accelerated localization of manufacturing or qualified alternate suppliers to mitigate exposure and preserve margin stability.

Procurement leaders have reacted by increasing focus on total cost of ownership and contractual mechanisms that hedge against tariff volatility. For example, multi-year supply agreements with fixed pricing clauses, joint inventory planning, and closer collaboration on demand forecasting have become more common as stakeholders seek predictability. In parallel, diagnostic companies have explored tariff engineering-adjusting bill of materials, assembly processes, or country-of-origin documentation-to minimize the tariff impact without compromising compliance.

Importantly, these tariff-related responses have secondary effects on clinical deployment cycles. Extended lead times for instrument shipments and constrained reagent availability can delay validation activities in diagnostic laboratories and slow rollout of new tests in ambulatory and hospital settings. Consequently, health systems and laboratories are placing greater emphasis on contingency planning and flexible validation protocols so clinical service continuity is preserved when supply chain interruptions occur. These adaptations are reshaping procurement playbooks and innovation timelines across the diagnostic ecosystem.

Segmentation-driven insights into how product architectures, end-user needs, and application priorities determine adoption patterns and procurement strategies

A granular segmentation analysis reveals meaningful differences in technology adoption and usage patterns across product types, end users, and applications. Within product types, instruments and equipment such as automated ELISA analyzers, immunoassay analyzers, and PCR systems are typically prioritized by high-throughput diagnostic laboratories and larger hospital systems where throughput, precision, and integration with laboratory automation are paramount. In contrast, kits and assay formats including ELISA kits, PCR test kits, and rapid test kits serve a broader array of settings; ELISA and PCR kits often underpin centralized laboratory workflows while rapid test kits enable near-patient decision-making in ambulatory care or hospital triage.

Reagents and consumables, encompassing antibodies, buffers and media, and enzymes and probes, represent the recurring operational spend that drives procurement and inventory strategies. End users differ in their procurement and validation imperatives: ambulatory care settings typically prioritize ease of use and rapid turnaround, diagnostic laboratories emphasize throughput and analytical robustness, hospitals and clinics require scalability and compatibility with clinical workflows, and research institutes often seek customizable reagents and the flexibility to support exploratory assays. Applications further segment the demand profile, as diagnostic use cases demand regulatory-grade validation and reproducibility, monitoring applications focus on serial sampling and longitudinal interpretation, research use prioritizes experimental flexibility, and screening requires high throughput, cost-effectiveness, and minimal false-positive rates.

Taken together, the interplay among product architecture, end-user operational constraints, and intended application informs product development priorities, go-to-market segmentation, and the structure of commercial partnerships across the diagnostic value chain.

Regional diagnostic landscapes and healthcare system nuances that shape adoption, reimbursement, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence diagnostic adoption pathways, reimbursement frameworks, and pathway integration for preterm birth and PROM testing. In the Americas, clinical decision-making is shaped by a mix of private and public payers, regional centers of excellence, and a strong emphasis on hospital and laboratory consolidation. This environment favors scalable instrument platforms and validated kits that can be deployed across integrated health systems, while also supporting localized innovation in academic centers.

Europe, Middle East & Africa features diverse regulatory landscapes and variable healthcare funding models, which create heterogenous adoption rates across countries. In many Western European markets, centralized reimbursement and robust clinical guidelines accelerate uptake of validated diagnostic tests, whereas in other parts of the region, constrained healthcare budgets and logistical barriers prioritize low-cost rapid tests and locally adaptable reagent solutions. Additionally, regional collaborations and cross-border research partnerships are playing an increasing role in evidence generation and guideline harmonization.

Asia-Pacific encompasses a fast-adopting mix of high-income healthcare systems and large emerging markets, where rapid urbanization and expanding prenatal care access drive demand for both high-throughput laboratory solutions and decentralized testing models. Local manufacturing hubs and government-supported initiatives aimed at strengthening perinatal care infrastructures are accelerating product localization and public-private partnerships. Across all regions, stakeholders are converging on the need for evidence of clinical utility, seamless integration into care pathways, and resilient supply chains to ensure continuous access to critical diagnostic testing.

Competitive forces, partnership strategies, and evidence-driven differentiation that determine which companies lead in preterm birth and PROM diagnostic innovation

Competitive dynamics in the preterm birth and PROM testing space are shaped by a mix of established diagnostics companies, specialized reagent suppliers, and agile innovators bringing point-of-care capabilities to market. Incumbent instrument manufacturers continue to compete on platform reliability, laboratory automation compatibility, and global service networks, while newer entrants differentiate through niche assay chemistries, simplified user interfaces, and rapid deployment models. Strategic partnerships and co-development agreements between instrumentation firms and assay developers have increased, enabling faster market entry and shared regulatory pathways.

Reagent and consumable suppliers that demonstrate consistent quality, validated supply chains, and packaging formats optimized for clinical laboratories gain preference among procurement teams. Meanwhile, companies that invest in clinical validation programs and publish real-world evidence can accelerate clinician adoption by proving not only analytical accuracy but also measurable impact on care decisions. Additionally, channel dynamics such as distributor relationships, direct sales to hospitals, and laboratory network agreements influence reach and uptake across geographies.

Overall, competitive advantage increasingly depends on the ability to align technical performance with operational resilience and evidence-based clinical value, creating opportunities for firms that can integrate across the diagnostic ecosystem and support customers across the lifecycle from implementation to post-market surveillance.

Actionable strategic priorities for diagnostic manufacturers and healthcare leaders focused on validation, resilient supply chains, flexible commercial models, and payer engagement

Industry leaders should prioritize a multi-pronged strategy that aligns product innovation with clinical validation, supply chain robustness, and payer engagement. First, investing in pragmatic clinical studies that demonstrate how diagnostic results change management decisions and improve maternal and neonatal outcomes will be critical to securing clinician buy-in and supporting reimbursement discussions. These studies should be designed with real-world workflows in mind and incorporate multicenter collaborations to enhance generalizability.

Second, strengthening supply chain resilience through dual sourcing, geographic diversification of manufacturing, and longer-term reagent stability initiatives will reduce operational risk and improve customer confidence. In parallel, offering flexible commercial models-such as reagent-as-a-service, reagent rental agreements for instruments, or bundled implementation packages-can lower adoption barriers for health systems and laboratories.

Third, leaders should engage proactively with payers, guideline-setting bodies, and hospital procurement committees to demonstrate the value proposition beyond test accuracy, highlighting downstream cost avoidance, reduced neonatal morbidity, and improved care pathways where evidence supports those outcomes. Finally, fostering interoperable platforms and open data standards will ease integration with hospital systems and enable value-added analytics that amplify the clinical utility of test results. By pursuing these complementary actions, manufacturers and stakeholders can accelerate adoption while mitigating commercial and operational risks.

A rigorous methodology combining primary expert interviews, technical documentation, and clinical literature synthesis to validate diagnostic performance and implementation considerations

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance documents, industry-available technical specifications, and primary interviews with clinicians, laboratory directors, and procurement professionals. The approach prioritized triangulation, combining evidence of analytical performance with insights about clinical utility and operational implementation drawn from real-world practice. Where regulatory guidance was relevant, interpretations focused on how guidance informs validation needs and post-market surveillance rather than on jurisdiction-specific compliance checklists.

Primary research included structured interviews with subject-matter experts across obstetrics, neonatology, clinical laboratory science, and hospital operations. Secondary research reviewed methodological papers on assay performance, published clinical studies examining outcomes related to PROM and preterm birth diagnostics, and supplier technical documentation that details platform capabilities and consumable requirements. Data synthesis emphasized thematic consistency across sources, and areas of divergent opinion are noted to highlight uncertainties and opportunities for targeted evidence generation.

Limitations of the methodology include variability in study designs and endpoints within the clinical literature, heterogeneity in local adoption pathways across regions, and evolving policy dynamics that may alter procurement incentives. To mitigate these limitations, findings were validated through multiple expert interviews and cross-checked against technical product literature to ensure that practical implementation considerations are well represented.

Concluding synthesis of diagnostic innovation, evidence expectations, and operational priorities that determine the future trajectory of preterm birth and PROM testing

In summary, the diagnostic landscape for preterm birth and PROM testing is undergoing rapid evolution driven by technological advances, higher evidentiary expectations, and operational imperatives. Clinicians and laboratory leaders are seeking diagnostics that deliver not only analytical reliability but also demonstrable clinical impact and seamless integration into care pathways. Supply chain continuity and tariff-related cost pressures are prompting strategic shifts in sourcing and contract design, affecting timelines for deployment and validation.

Segmentation insight indicates that instruments and high-throughput platforms will remain central to hospital and laboratory strategies, while rapid and point-of-care kits will expand access in ambulatory settings and emergency triage. Reagents and consumables continue to shape recurring procurement dynamics, and applications spanning diagnosis, monitoring, research use, and screening create differentiated requirements for validation and workflow integration. Regionally, the interplay of reimbursement, regulatory frameworks, and local manufacturing capacity will continue to produce heterogeneous adoption pathways.

For stakeholders intent on advancing prenatal diagnostics, the clear priorities are robust clinical validation, resilient and transparent supply models, and closer engagement with payers and guideline committees. These priorities will determine which innovations translate into sustainable clinical uptake and improved maternal and neonatal outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preterm Birth & PROM Testing Market, by Product Type

  • 8.1. Instruments & Equipment
    • 8.1.1. Automated Elisa Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. Pcr Systems
  • 8.2. Kits & Assay Kits
    • 8.2.1. Elisa Kits
    • 8.2.2. Pcr Test Kits
    • 8.2.3. Rapid Test Kits
  • 8.3. Reagents & Consumables
    • 8.3.1. Antibodies
    • 8.3.2. Buffers & Media
    • 8.3.3. Enzymes & Probes

9. Preterm Birth & PROM Testing Market, by Technology

  • 9.1. Biochemical Assays
  • 9.2. Molecular Diagnostics
  • 9.3. Biophysical & Imaging Methods

10. Preterm Birth & PROM Testing Market, by Biomarker

  • 10.1. Protein Biomarkers
  • 10.2. Genetic And Genomic Markers
  • 10.3. Microbial And Infection Markers

11. Preterm Birth & PROM Testing Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Research Institutes

12. Preterm Birth & PROM Testing Market, by Application

  • 12.1. Diagnosis
  • 12.2. Monitoring
  • 12.3. Research Use
  • 12.4. Screening

13. Preterm Birth & PROM Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preterm Birth & PROM Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preterm Birth & PROM Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Preterm Birth & PROM Testing Market

17. China Preterm Birth & PROM Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. bioMerieux SA
  • 18.7. Danaher Corporation
  • 18.8. Eurofins Scientific SE
  • 18.9. Hologic, Inc.
  • 18.10. Qiagen N.V.
  • 18.11. Quidel Corporation
  • 18.12. Revvity, Inc.
  • 18.13. Rhomed S.p.A.
  • 18.14. Roche Diagnostics GmbH
  • 18.15. Sekisui Medical Co., Ltd.
  • 18.16. Sera Prognostics, Inc.
  • 18.17. Siemens Healthineers AG
  • 18.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOPHYSICAL & IMAGING METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PROTEIN BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GENETIC AND GENOMIC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MICROBIAL AND INFECTION MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 174. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 211. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)